الأحد 7 جمادى الأولى 1448هـ
جميع روابط المواقع الرسمية التابعة للجهات الحكومية في المملكة العربية السعودية تنتهي بـ .gov.sa
تحقق من أن الموقع يستخدم بروتوكول HTTPS
مسجل لدى هيئة الحكومة الرقمية برقم :
| عنوان الدراسة | داعم الدراسة | حالة الدراسة | دواء الدراسة | مرحلة الدراسة | رقم بروتوكول الدراسة | موقع الدراسة |
|---|---|---|---|---|---|---|
| A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa | AbbVie Biopharmaceuticals GmbH ScientificOffice | Ongoing | Lutikizumab | 3 | M20-465 | King Khalid University Hospital (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh), King Faisal Specialist Hospital and Research Center (Jeddah), King Abdulaziz Medical City NG (Jeddah) |
| Real-world evidence Non-Interventional proSpective study of kisqaLi (Ribociclib) Effectiveness and safety in patients with HR+/HER2- early Breast Cancer in Saudi Arabia | Novartis Saudi Ltd | Ongoing | kisqaLi (ribociclib) | 2 | CLEE011ASA | King Abdulaziz Medical City NG (Riyadh), King Khalid University Hospital (Riyadh) |
| A Phase III, Randomised, Double-blind, Placebo-controlled, Event-driven Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on Renal Outcomes and Cardiovascular Mortality in Participants with Chronic Kidney Disease and High Blood Pressure | Astrazeneca | Ongoing | D6972C00002 | 3 | D6972C00002 | King Faisal Specialist Hospital and Research Center (Riyadh) ,King Fahad Specialist Hospital (Dammam) ,King Fahad Medical City (Riyadh) ,King Abdulaziz Hospital NG (Al Ahsa), King Abdulaziz Medical City NG (Riyadh) |
| Weight Maintenance in Adolescents With Obesity; Long-Term Treatment With Semaglutide s.c 2.4 mg Once-weekly | Novo Nordisk | Ongoing | Semaglutide | 3 | NN9536-7752 | King Khalid University Hospital (Riyadh) ,King Abdulaziz Medical City NG (Riyadh), King Abdulaziz Hospital NG (Al Ahsa), King Abdulaziz Medical City NG (Jeddah) ,King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Global, Phase 1/2, Open-label, Dose Optimization Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of mRNA-3927 in Participants with Propionic Acidemia | Moderna | Ongoing | mRNA-3927 | 1/2 | mRNA-3927-P101 | King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh) |
| King Abdullah International Medical Research Center’s (KAIMRC) | Ongoing | Brentuximab Vedotin + AVD (Adriamycin, Vinblastine & Dacarbazine | 2 | RJ19/119/J | King Abdullah Medical Complex (Jeddah) | |
| King Faisal Specialist Hospital and Research Center (Jeddah) | Ongoing | Insulin | 3 | 2023-45 | King Faisal Specialist Hospital and Research Center (Jeddah) | |
| Inozyme Pharma, Inc | Ongoing | INZ701 | 3 | INZ701-106 | King Faisal Specialist Hospital and Research Center (Riyadh) | |
| AbbVie | Ongoing | Risankizumab | 3 | M23-784 | King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh), King Fahad Specialist Hospital (Dammam) | |
| Astrazeneca | Ongoing | Anifrolumab | 4 | TMP-0010230 | Aseer Central Hospital (Abha), International Medical Center (Jeddah), King Khalid University Hospital (Riyadh) |
تاريخ آخر تحديث: 06/10/2026 بتمام الساعة 08:14 صباحا بتوقيت المملكة العربية السعودية
لم يتم تقديم أي تقييمات لهذه الصفحة بعد.
التعليقات والاقتراحات
لأي استفسارات أو ملاحظات حول الخدمات الحكومية، يرجى تعبئة المعلومات المطلوبة.